Capricor rises as FDA extends Deramiocel action date
The news indicates that the stock price has risen following the FDA's extension of the review (action) deadline for Deramiocel.
The current price of $6.80 is positioned between the 20-day resistance level ($8.29) and the support level ($2.96), suggesting that entry could be considered during this phase of a pullback or resistance level test following a short-term surge. I will monitor the RSI (14) at 64.1 and the recent 7-day volatility of +50.1% to assess the potential for a breakout above the resistance level.
If the stock price reaches the resistance level of $8.29, I will take profits, and if it falls below the support level of $2.96, I will cut losses — considering that this is a phase of a short-term surge followed by a pullback or a test of the resistance level, I will respond mechanically only when the reference values are reached.
The technical indicators at the entry point show an RSI(14) of 64.1, a non-aligned moving average, a trading volume at 0.68 times the 20-day average, and a recent 7-day volatility of +50.1%. The RSI is above 60, indicating upward pressure, and while there has been a strong volatility of +50.1% over the last 7 days, the trading volume is somewhat limited at 0.68 times the 20-day average.
Based on past similar history, there were price reactions of +20.0% on 2026-08-14, +89.5% on 2026-08-13, and +0.2% on 2026-07-30. This stock has shown a pattern of strong upward volatility when positive events occur; however, there have been instances, such as on July 30, where the reaction was minimal. This indicates that the magnitude of the stock price response can vary depending on the intensity of individual events.
Based on the volatility at the forecast point (+50.1%) and the RSI (14) of 64.1, we monitored movements near the resistance level and anticipated a return of 4.5%. However, the actual result recorded a 16.5% increase, resulting in an OVERHIT designation. Coupled with the positive event of the extension of the Deramiocel review deadline, we can confirm that the strong upward volatility pattern observed in past similar histories has translated into actual price response.
Through this trading activity, we have once again confirmed the strong upward volatility characteristics that this stock exhibits during positive events. In the future, when similar positive news coincides with technical trends, we will not only set conservative target prices but also keep the possibility of additional volatility expansion open and adjust our response strategy flexibly.